Active programs include developing dual-effect liposomes that combines the advantages of photodynamic therapy and chemotherapy for cancer therapy, human vaccine production and adjuvants formulation to produce the effective vaccine or drug against the disease. Several global clinical proof of concept studies are scheduled in the next few years with exit points to collaborate with global large pharma and commercialization.